Browse our anti-RAMP2 (RAMP2) Antibodies

Mouse (Murine) Receptor (G Protein-Coupled) Activity Modifying Protein 2 (RAMP2) interaction partners

1. the cardiovascular response of Ramp1 (show RAMP1 Antibodies)(-/-), Ramp2(+/-), Ramp3 (show RAMP3 Antibodies)(-/-), Ramp1 (show RAMP1 Antibodies)(-/-)/Ramp3 (show RAMP3 Antibodies)(-/-) double-knockout (dKO), and Calcrl (show CALCRL Antibodies)(+/-) mice to AM and CGRP (show CALCA Antibodies) were compared to wildtype mice.These results suggest that the hypotensive effect of AM is primarily mediated through the CLR (show CALCR Antibodies)/RAMP1 (show RAMP1 Antibodies) heterodimer, but that AM signaling via CLR (show CALCR Antibodies)/RAMP2 and CLR (show CALCR Antibodies)/RAMP3 (show RAMP3 Antibodies) also contributes to some hypotensive action.

2. The AM-RAMP2 system exerts crucial vasoprotective effects after vascular injury and could be a therapeutic target for the treatment of vascular diseases.

3. Results provide in vivo evidence of a role for RAMP2 in placental development distinct from the RAMP2-calcitonin receptor-like receptor (show CALCRL Antibodies)/adrenomedullin (show ADM Antibodies) signaling paradigm; decreases Pthr1 (show PTH1R Antibodies) expression and causes a blunted response to systemic parathyroid hormone (show PTH Antibodies); and identify additional pathways underlying the endocrine and fertility defects of the previously characterized Ramp2 heterozygous adult females.

4. the Adrenomedullin (show ADM Antibodies)-RAMP2 system regulates vascular integrity, whereas RAMP2 deletion promotes vascular permeability

5. RAMP2 is essential for early vascular development and knockout-mice die in utero.

6. These results indicate the AM-RAMP2 system works to protect nerve cells from both acute and chronic cerebral ischemia by maintaining cerebral blood flow suppressing oxidative stress, and in the case of chronic ischemia, enhancing capillary growth.

7. The AM-RAMP2 system is a key determinant of vascular integrity and homeostasis from prenatal stages through adulthood.

8. These data demonstrate that the adrenomedullin (show ADM Antibodies)-RAMP2 system is essential for cardiac metabolism and homeostasis.

9. Data show that mechanical ventilation reduced the expression of receptor activity-modifying protein RAMP3 (show RAMP3 Antibodies), but not of intermedin (IMD (show ADM2 Antibodies)), calcitonin receptor-like receptor (CRLR (show CALCRL Antibodies)), and RAMP1 (show RAMP1 Antibodies) and RAMP2.

10. Adrenomedullin (show ADM Antibodies)-RAMP2 system is the potential target for the induction of liver sinusoidal endothelial cells.

Human Receptor (G Protein-Coupled) Activity Modifying Protein 2 (RAMP2) interaction partners

1. Single nucleotide polymorphism of RAMP2 is associated with Stroke.

2. This work suggests that RAMP2 may modify the agonist activity and trafficking of the GCGR (show GCGR Antibodies), with potential relevance to production of new peptide analogs with selective agonist activities.

3. Data suggest that a single GlcNAc residue at CTR (show CALCR Antibodies) N130 (asparagine 130) is responsible for enhanced affinity of calcitonin (show CALCA Antibodies) for CTR (show CALCR Antibodies) ECD (show SHFM1 Antibodies); the same appears to apply for enhanced affinity of amylin (show IAPP Antibodies) for RAMP2-CTR (show CALCR Antibodies) ECD (show SHFM1 Antibodies). [GlcNAc = N-acetylglucosamine; CTR (show CALCR Antibodies) = calcitonin receptor (show CALCR Antibodies); ECD (show SHFM1 Antibodies) = extracellular domain; RAMP2 = receptor (calcitonin) activity modifying protein 2].

4. interaction of RAMP2 or RAMP3 (show RAMP3 Antibodies) with CLR (show DCLK3 Antibodies) induces conformational variation in the juxtamembrane region, yielding distinct binding pockets, probably via an allosteric mechanism.

5. This study reveals the glucagon receptor (show GCGR Antibodies) as a previously unidentified target for GLP-1 receptor (show GLP1R Antibodies) agonists and highlights a role for RAMP2 in regulating its pharmacology.

6. Data suggest that ligand binding of a G protein-coupled receptor (GPCR (show TAS1R3 Antibodies)) may inform drug development targeting calcitonin receptor-like receptor (CLR (show CALCRL Antibodies)):receptor activity-modifying proteins RAMP1 (show RAMP1 Antibodies)/2 complexes.

7. the AM system is widely expressed in human thymus from newborns; both AM1 receptor components CLR (show DCLK3 Antibodies) and RAMP2, but not RAMP3 (show RAMP3 Antibodies), are not associated with the plasma membrane of TECs and thymocytes but are located intracellularly, notably in the nucleus

8. Adrenomedullin (show ADM Antibodies)-RAMP2 system suppresses ER stress-induced tubule cell death and is involved in kidney protection.

9. Data suggest isoforms of RAMP modulate accessibility of peptides to residues situated on CALCRL (calcitonin receptor-like receptor (show CALCRL Antibodies)) N-terminal domain; RAMP3 (show RAMP3 Antibodies)/RAMP2/RAMP1 (show RAMP1 Antibodies) appear to alter accessibility of specific residues at CALCRL (show CALCRL Antibodies)-RAMP interface.

10. RAMP2 gene expression increases with gestational age development in the fetal lung.

Cow (Bovine) Receptor (G Protein-Coupled) Activity Modifying Protein 2 (RAMP2) interaction partners

1. Data indicate that adrenomedullin (show ADM Antibodies) mRNA and protein signal were only found in trophoblast binucleate cells (BNCs), whereas those of CRLR (show CALCRL Antibodies), RAMP2 and RAMP3 (show RAMP3 Antibodies) were detected in cotyledonary villous and caruncular epithelial cells.